Laser Treatment in Patients with Bilateral Large Drusen. The Complications of Age-Related Macular Degeneration Prevention Trial

Ophthalmology

Volumn 113, Issue 11, 2006, Pages 1974-1986

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CATARACT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUSEN; FEMALE; HUMAN; INCIDENCE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SUBRETINAL NEOVASCULARIZATION;

AGED; CHOROIDAL NEOVASCULARIZATION; CONTRAST SENSITIVITY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LASERS; MACULAR DEGENERATION; MALE; READING; RETINAL DRUSEN; TIME FACTORS; TREATMENT FAILURE; VISION DISORDERS; VISUAL ACUITY;

EID: 33750322896     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.08.015     Document Type: Article

References (44)

1. Bressler S.B., Maguire M.G., Bressler N.M., et al. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. Arch Ophthalmol 108 (1990) 1442-1447
2. Macula Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 115 (1997) 741-747
3. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss. AREDS report no. 8. Arch Ophthalmol 119 (2001) 1417-1436
4. Klein R., Klein B.E., Tomany S.C., et al. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 109 (2002) 1767-1779
5. Cleasby G.W., Nakanishi A.S., and Norris J.L. Prophylactic photocoagulation of the fellow eye in exudative senile maculopathy: a preliminary report. Mod Probl Ophthalmol 20 (1979) 141-147
6. Wetzig P.C. Treatment of drusen-related aging macular degeneration by photocoagulation. Trans Am Ophthalmol Soc 86 (1988) 276-290
7. Sigelman J. Foveal drusen resorption one year after perifoveal laser photocoagulation. Ophthalmology 98 (1991) 1379-1383
8. Figueroa M.S., Regueras A., and Bertrand J. Laser photocoagulation to treat macular soft drusen in age-related macular degeneration. Retina 14 (1994) 391-394
9. Frennesson I.C., and Nilsson S.E. Laser photocoagulation of soft drusen in early age-related maculopathy (ARM): the one-year results of a prospective, randomised trial. Eur J Ophthalmol 6 (1996) 307-314
10. Sarks S.H., Arnold J.J., Sarks J.P., et al. Prophylactic perifoveal laser treatment of soft drusen. Aust N Z J Ophthalmol 24 (1996) 15-26
11. Guymer R.H., Gross-Jendroska M., Owens S.L., et al. Laser treatment in subjects with high-risk clinical features of age-related macular degeneration: posterior pole appearance and retinal function. Arch Ophthalmol 115 (1997) 595-603
12. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen: short-term effects seen in pilot randomized clinical trial. Ophthalmology 105 (1998) 11-23
13. Olk R.J., Friberg T.R., Stickney K.L., et al. Therapeutic benefits of infrared (810 nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study. Ophthalmology 106 (1999) 2082-2090
14. Rodanant N., Friberg T.R., Cheng L., et al. Predictors of drusen reduction after subthreshold infrared (810 nm) diode laser macular grid photocoagulation for nonexudative age-related macular degeneration. Am J Ophthalmol 134 (2002) 577-585
15. Little H.L., Showman J.M., and Brown B.W. A pilot randomized controlled study on the effect of laser photocoagulation of confluent soft macular drusen. Ophthalmology 104 (1997) 623-631
16. Ho A.C., Maguire M.G., Yoken J., et al. Laser-induced drusen reduction improves visual function at one year. Ophthalmology 106 (1999) 1367-1373 discussion 1374
17. Frennesson C.I. Prophylactic laser treatment in early age-related maculopathy: an 8-year follow-up in a randomized pilot study shows a reduced incidence of exudative complications. Acta Ophthalmol Scand 81 (2003) 449-454
18. Scorolli L., Corazza D., Morara M., et al. Argon laser vs. subthreshold infrared (810-nm) diode laser macular grid photocoagulation in nonexudative age-related macular degeneration. Can J Ophthalmol 38 (2003) 489-495
19. Hyver S.W., Schatz H., McDonald H.R., and Johnson R.N. A case of visual acuity loss following laser photocoagulation for macular drusen. [letter]. Arch Ophthalmol 115 (1997) 554-555
20. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in fellow eyes with large drusen. Updated findings from a pilot randomized clinical trial. Ophthalmology 110 (2003) 971-978
21. Friberg T.R., Musch D.C., Lim J.I., et al. Prophylactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients. Ophthalmology 113 (2006) 612-622
22. Owens S.L., Bunce C., Brannon A.J., et al. Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the Drusen Laser Study. Am J Ophthalmol 141 (2006) 276-281
23. Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clin Trials 1 (2004) 91-107
24. Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). Ophthalmology 111 (2004) 1307-1316
25. Early Treatment Diabetic Retinopathy Study: design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 98 suppl (1991) 741-756
26. National Eye Institute. Age-Related Eye Disease Study. Manual of operations (MOP). Examination procedures (2000). https://web.emmes.com/study/areds/mopfiles/chp7_mop.pdf 7-1-12, Available at: https://web.emmes.com/study/areds/mopfiles/chp7_mop.pdf. Accessed August 9, 2006.
27. Pelli D.G., Robson J.G., and Wilkins A.J. The design of a new letter chart for measuring contrast sensitivity. Clin Vis Sci 2 (1988) 187-199
28. Mansfield J.S., Legge G.E., and Bane M.C. Psychophysics of reading. XV: font effects in normal and low vision. Invest Ophthalmol Vis Sci 37 (1996) 1492-1501
29. Klein R., Davis M.D., Magli Y.L., et al. The Wisconsin Age-Related Maculopathy Grading System. Ophthalmology 98 (1991) 1128-1134
30. Bird A.C., Bressler N.M., Bressler S.B., and International ARM Epidemiological Study Group. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 39 (1995) 367-374
31. Holz F.G., Wolfensberger T.J., Piguet B., et al. Bilateral macular drusen in age-related macular degeneration: prognosis and risk factors. Ophthalmology 101 (1994) 1522-1528
32. Zeger S.L., and Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42 (1986) 121-130
33. Wei L.J., Lin D.Y., and Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 84 (1989) 1065-1073
34. O'Brien P.C., and Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556
35. Lan K.K., and DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika 70 (1983) 649-653
36. Gass J.D. Photocoagulation of macular lesions. Trans Am Acad Ophthalmol Otolaryngol 75 (1971) 580-608
37. Ruiz-Moreno J.M., De La Vega C., and Zarbin M.A. Macular atrophy after photocoagulation of soft drusen. Retina 23 (2003) 315-321
38. Heier J.S., Antoszyk A.N., Pavan P.R., et al. Ranibizumab for treatment of neovascular age-related macular degeneration. A phase I/II multicenter, controlled, multidose study. Ophthalmology 113 (2006) 633-642
39. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 111 (1993) 1200-1209
40. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 119 (2001) 198-207
41. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 131 (2001) 541-560
42. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
43. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results. AREDS report no. 11. Arch Ophthalmol 121 (2003) 1621-1624
44. Kaiser R.S., Berger J.W., Maguire M.G., et al. Laser burn intensity and the risk for choroidal neovascularization in the CNVPT Fellow Eye Study. Arch Ophthalmol 119 (2001) 826-832